Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05624450 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
A Phase 3 study of Viral Lung Infection and Acute Respiratory Failure, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 2,870
- Enrollment target
- 20
- Study locations
NCT05624450 is a Phase 3 study of Viral Lung Infection and Acute Respiratory Failure that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 2,870 participants. The trial reports 20 study locations across 6 states.
The verdict
NCT05624450, a Phase 3 study of Viral Lung Infection and Acute Respiratory Failure, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,870 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tozorakimab
Study Locations (20)
Florida
- Research Site - Bradenton
- Research Site - Bradenton
- Research Site - Gainesville
- Research Site - Jacksonville
- Research Site - Lakeland
- Research Site - Miami
- Research Site - South Pasadena
California
- Research Site - Chula Vista
- Research Site - Fresno
- Research Site - La Mesa
- Research Site - Los Angeles
- Research Site - Newport Beach
- Research Site - Torrance
Arizona
- Research Site - Phoenix
- Research Site - Phoenix
- Research Site - Tucson
Colorado
- Research Site - Colorado Springs
- Research Site - Denver
Alabama
- Research Site - Mobile
District of Columbia
- Research Site - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,870 participants |
| Start Date | 2022-12-13 |
| Est. Completion | 2026-06-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05624450
The ClinicalTrials.gov registry entry for NCT05624450 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 2,870 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Viral Lung Infection and Acute Respiratory Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05624450 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT05624450 about?
NCT05624450 is a clinical study titled "Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen". The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
What is the current status of trial NCT05624450?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 2,870 participants. The study started on 2022-12-13. Estimated completion is 2026-06-19.
What conditions does trial NCT05624450 study?
This clinical trial studies the following conditions: Viral Lung Infection and Acute Respiratory Failure.
What interventions are being tested in trial NCT05624450?
The interventions under investigation include: Placebo (DRUG), Tozorakimab (DRUG).
Who is sponsoring clinical trial NCT05624450?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05624450 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.